Last $0.05 USD
Change Today 0.00 / 0.00%
Volume 0.0
VNAPF On Other Exchanges
Symbol
Exchange
London
OTC US
As of 4:30 PM 04/25/14 All times are local (Market data is delayed by at least 15 minutes).

verona pharma plc (VNAPF) Snapshot

Open
--
Previous Close
$0.05
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
1.0B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERONA PHARMA PLC (VNAPF)

Related News

No related news articles were found.

verona pharma plc (VNAPF) Related Businessweek News

No Related Businessweek News Found

verona pharma plc (VNAPF) Details

Verona Pharma plc, a biotechnology company, is engaged in the research, discovery, and development of therapeutic drugs in the United Kingdom and Canada. The company develops drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, allergic rhinitis (hay fever), and cough. Its lead drug compound include RPL554, a bronchodilator/anti-inflammatory drug that has completed Phase I and II clinical trials to treat asthma and COPD. The company is also developing VRP700, an anti-tussive drug, which has Phase II clinical trial for the treatment of cough, as well as novel anti-inflammatory polysaccharides (NAIPs) that in the basic research phase to treat respiratory and inflammatory diseases. The company is based in London, the United Kingdom.

10 Employees
Last Reported Date: 07/3/14

verona pharma plc (VNAPF) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 330.4K GBP
Executive Director and Member of Audit Commit...
Total Annual Compensation: 42.0K GBP
Compensation as of Fiscal Year 2013.

verona pharma plc (VNAPF) Key Developments

Verona Pharma plc Appoints Kenneth Newman as Chief Medical Officer, Effective January 1, 2015; Announces Incorporation of Verona Pharma, Inc

Verona Pharma plc announced the appointment of Kenneth Newman, M.D., M.B.A. to the newly created position of Chief Medical Officer, with effective from 1 January 2015. Dr. Newman will be based in the US and provide his expertise to support the company's global activities. Dr. Newman is an experienced pharmaceutical and biotechnology industry executive with extensive leadership experience in clinical development, including a number of orally inhaled drugs for the treatment of respiratory disease. Dr. Newman will join Verona Pharma from Mesoblast Inc, where he was Chief Development Officer and Head of Global Clinical Development. The appointment and the creation of the US affiliate reflects the continuing focus of Verona Pharma on advancing the clinical development and commercialization of its lead pipeline drug, RPL554, a first-in-class PDE3/PDE4 inhibitor currently in phase II development for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. The company also announced the incorporation of its fully owned subsidiary, Verona Pharma Inc.

Verona Pharma plc Announces Executive Changes, Effective Dec. 1, 2014

Verona Pharma plc announced the appointment of David Raymond Ebsworth as Non-Executive Chairman of the Board of Directors with effect from December 1. Ebsworth will succeed Clive Page, who has held the role since founding the company in 2006. Ebsworth has been involved in successful product approvals in the US and Europe. From October 2009 to August 2014, Ebsworth served as Chief Executive Officer of Vifor Pharma. He was also named as CEO of Galenica AG in 2011. Ebsworth had worked for over 19 years in Bayer AG.

Verona Pharma plc Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 11:25 AM

Verona Pharma plc Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 11:25 AM. Venue: Apella, 450 East 29th Street, New York, New York, United States. Speakers: Jan Anders Karlsson.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNAPF:US $0.05 USD 0.00

VNAPF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VNAPF.
View Industry Companies
 

Industry Analysis

VNAPF

Industry Average

Valuation VNAPF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 0.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERONA PHARMA PLC, please visit www.veronapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.